Viridian's Lumvoa emerging as rival to Amgen's Tepezza, BofA Securities says
FROM THE WIRE · FINANCE.YAHOO.COM
Viridian Therapeutics' (VRDN) Lumvoa is emerging as a "credible" competitor to Amgen's (AMGN) Tepezz Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news Full access to Financial Times and MT Newswires articles Stock picks Expert picks…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA credible competitor to an Amgen drug can affect the product's revenue outlook.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01BofA Securities calls Viridian Therapeutics' Lumvoa a "credible" competitor to Amgen's Tepezza.
- 02Most of the article is behind a subscription paywall.
- 03The reference concerns the VRDN and AMGN stocks.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Amgen Inc.437.56 USD+0.13%today -1.43%Negative Viridian Therapeutics, Inc.30.77 USD+0.11%today +2.14%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets